Creating cell lines with future manufacturability, cost of goods and speed in mind is of critical importance. How can time to the clinic be reduced and yet a drug candidate be equipped with a robust CMC-package from day one?

Join Megan Mason, head of Cell Culture Development at Lonza Biologics to learn how you can chart an optimal path from gene to the clinic by tailoring your cell line development program to match your molecule type, timelines, yield requirements and risk priorities.

You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center